1. Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. The scope of the Study
2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.3. Analytics Tools & Model
2.4. Economic Indicators
2.4.1.Base Year, Base Currency & Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
3. Market Analysis
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1 Bargaining Power of Suppliers
3.2.2 Bargaining Power of Buyers
3.2.3 Threat of Substitutes
3.2.4 Threat of New Entrants
3.2.5 Industry Rivalry (Competitive Environment)
3.3. PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4. SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.4.5 Y-O-Y Analysis
4. Market Dynamics
4.1. Drivers
4.1.1 Increasing demand for SPECT and PET analysis.
4.1.2 Development of better instruments.
4.1.3 New 99mTc labelled agents for visualising biologically significant events.
4.1.4. Newer computer-based procedures for image analysis and display.
4.2. Restraints
4.2.1 Shorter lifetime of radioisotopes.
4.2.2 Reimbursement issues.
4.2.3. Regulatory guidelines.
4.3. Opportunities
4.3.1 Increasing demand for PET imaging products which include hybrid PET-CT scanners will increase the growth of the market during the forecast.
4.4. Challenges
4.4.1. Shortage of molybdenum-99 isotope which in turn lead to a deficiency of technetium-99 which by-product of molybdenum.
5 Asia-Pacific Nuclear Medicine Diagnostic Market - By Types of radioisotopes
5.1 Introduction
5.2 SPECT
5.2.1 Technetium
5.2.2 Thallium
5.2.3 Gallium
5.3 PET
5.3.1 Fluorine
5.3.2 Rubidium
5.4 Beta-emitters
5.4.1 Phosphorous 32
5.4.2 Iodine 131
5.4.3 Strontium 89
5.4.4 Yttrium 90
5.4.5 Samarium 153
5.4.6 Rhenium 186/188
5.5 Alpha emitters
5.5.1 Radium 223
5.5.2 Bismuth 213
5.6 Brachytherapy
5.6.1 Palladium 103
5.6.2 Iodine 125
5.6.3 Cesium 131
6. Asia-Pacific Nuclear Medicine Diagnostic Market - By Application
6.1. Introduction
6.2 PET application
6.2.1 Oncology
6.2.2 Cardiology
6.2.3 Neurology
6.3 Therapeutic application
6.3.1 Thyroid
6.3.2 Bone metastasis
6.3.3 Lymphoma
6.3.4 Endocrine tumors
6.4 Diagnostics application
6.4.1 SPECT application
6.4.1.1 Cardiology
6.4.1.2 Neurology
6.4.1.3 Thyroid
7. Asia-Pacific Nuclear Medicine Diagnostic Market - By Country
7.1. Introduction
7.2. APAC
7.2.1.China
7.2.2. India
7.2.3. Japan
7.2.3. South Korea
7.2.5. Australia & New Zealand
7.2.6. Rest Of APAC
8. Asia-Pacific Nuclear Medicine Diagnostic Market - Company Profiles
8.1 GE health care
8.2 Siemens healthcare
8.3 Cardinal health care
8.4 Triad isotope
8.5 Nordion Inc.
8.6 Eczacibasi-monrol nuclear products
8.7 Mallinckrodt Plc
8.8 Bracco imaging S.p.A
8.9 Advanced accelerator applications SA
8.10 Lantheus medical imaging Inc.
8.11 IBA molecular imaging
8.12 Bayer healthcare
9. Asia-Pacific Nuclear Medicine Diagnostic Market - Competitive Landscape
9.1. Market Share Analysis
9.2. Strategies Adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
11. Appendix
11.1. List of tables
11.2. List of figures
